Also known as Nigella sativa, Black cumin seed oil
Oil pressed from Nigella sativa seeds; its active compound thymoquinone has shown anti-inflammatory and antioxidant activity in trials, and is studied for metabolic, respiratory, and immune outcomes.
We link to relevant studies and leave interpretation to you and your healthcare professional.
Number of audited published findings for Black Seed Oil by condition. Drill into a pair page for the full breakdown.
Where people report using it and what trials suggest
Common claims the trials do not support
Nigella sativa oil (thymoquinone) with consistent but small-trial metabolic improvements; effect sizes modest, quality moderate.
Safety notes: Topical use causes allergic contact dermatitis in some; GI upset; avoid high doses in pregnancy.
Evidence grades reflect study quality and consistency, not marketing claims.
Summaries of published trial results for this compound, grouped by condition. Numbers are reported exactly as the researchers published them — we never calculate or convert.
How to read this table
In short: benefit is what was observed; evidence is how much you should trust the observation. A “Benefit seen” tag on a weak study counts for far less than the same tag on a meta-analysis.
| Outcome measured | What trials found | Effect size | People studied | Duration | Type of evidence | Study |
|---|---|---|---|---|---|---|
| glutathione peroxidase (GPx) | GPx levels significantly improved by SMD 1.23 in 1086 participants compared to control. (95% CI 0.25, 2.22; p=0.014)Benefit seen | 1.23 SMD | 1086 | — | Meta-analysis · 2023 | PMID 37036558 |
| interleukin 6 (IL-6) | No significant reduction in IL-6 levels found in 1086 participants compared to control. (SMD=-1.13; 95% CI -2.72, 0.46, p=0.162)No clear benefit | no number reported | 1086 | — | Meta-analysis · 2023 | PMID 37036558 |
Associated conditions and community-reported outcomes, wrapped together on one page. Aggregates appear only once enough reports arrive.
How this compound is sold in the UK, and where our readers typically find it.
Retailer search links — we may earn commission on purchases at no cost to you. Commission never affects our evidence ratings.
| malondialdehyde (MDA) |
| MDA levels significantly reduced by SMD -2.15 in 1086 participants compared to control. (95% CI -3.37, -0.93, p<0.001)Benefit seen |
| -2.15 SMD |
| 1086 |
| — |
| Meta-analysis · 2023 |
| PMID 37036558 |
| serum C-reactive protein (CRP) | CRP levels significantly reduced by SMD -2.28 in 1086 participants compared to control. (95% CI -3.20, -1.37, p<0.001)Benefit seen | -2.28 SMD | 1086 | — | Meta-analysis · 2023 | PMID 37036558 |
| superoxide dismutase (SOD) | SOD levels significantly improved by SMD 2.05 in 1086 participants compared to control. (95% CI 1.22, 2.88, p<0.001)Benefit seen | 2.05 SMD | 1086 | — | Meta-analysis · 2023 | PMID 37036558 |
| total antioxidant capacity (TAC) | TAC levels significantly improved by SMD 2.28 in 1086 participants compared to control. (95% CI 1.29, 3.27, p<0.001)Benefit seen | 2.28 SMD | 1086 | — | Meta-analysis · 2023 | PMID 37036558 |
| tumour necrosis factor α (TNFα) | TNFα levels significantly reduced by SMD -1.21 in 1086 participants compared to control. (95% CI -2.15, -0.26; p=0.013)Benefit seen | -1.21 SMD | 1086 | — | Meta-analysis · 2023 | PMID 37036558 |
| high-sensitivity C-reactive protein (hs-CRP) | hs-CRP levels decreased by 0.67 units compared to control in a meta-analysis of 10 trials. (95% CI: -1.29, -0.05)Benefit seen | -0.67 | — | — | Meta-analysis · 2021 | PMID 33559935 |
| malondialdehyde (MDA) | MDA levels decreased by 1.18 units compared to control in a meta-analysis of 10 trials. (95% CI: -2.24, -0.12)Benefit seen | -1.18 | — | — | Meta-analysis · 2021 | PMID 33559935 |
| superoxide dismutase (SOD) | SOD levels increased by 66.30 units compared to control in a meta-analysis of 10 trials. (95% CI: 1.03, 131.57)Benefit seen | 66.30 | — | — | Meta-analysis · 2021 | PMID 33559935 |
| total antioxidant capacity (TAC) | TAC levels increased by 0.35 units compared to control in a meta-analysis of 10 trials. (95% CI: 0.10, 0.59)Benefit seen | 0.35 | — | — | Meta-analysis · 2021 | PMID 33559935 |
| tumor necrosis factor-alpha (TNF-α) | TNF-α levels decreased by 2.29 units compared to control in a meta-analysis of 10 trials. (95% CI: -4.48, -0.11)Benefit seen | -2.29 | — | — | Meta-analysis · 2021 | PMID 33559935 |
| high sensitivity C-reactive protein | No significant difference in high sensitivity C-reactive protein vs placebo or no supplementation in 267 participants. (95% CI=-1.98-0.03)No clear benefit | no number reported | 267 | — | Meta-analysis · 2021 | PMID 34187123 |
| Interleukin 6 (IL-6) | No significant difference in Interleukin 6 vs placebo or no supplementation in 134 participants. (95% CI=-0.65 to 0.16)No clear benefit | no number reported | 134 | — | Meta-analysis · 2021 | PMID 34187123 |
| malondialdehyde | No significant difference in malondialdehyde vs placebo or no supplementation in 179 participants. (95% CI=-1.97-0.08)No clear benefit | no number reported | 179 | — | Meta-analysis · 2021 | PMID 34187123 |
| superoxide dismutase | Superoxide dismutase levels increased by 63.79 µ/gHb vs placebo or no supplementation in 88 participants. (95% CI=6.84-120.75)Benefit seen | 63.79 µ/gHb | 88 | — | Meta-analysis · 2021 | PMID 34187123 |
| total antioxidant capacity | Total antioxidant capacity increased by 0.34 mmol/L vs placebo or no supplementation in 232 participants. (95% CI=0.04 to 0.63)Benefit seen | 0.34 mmol/L | 232 | — | Meta-analysis · 2021 | PMID 34187123 |
| Tumor Necrosis Factor alpha (TNF-α) | TNF-α levels decreased by 2.15 pg/mL vs placebo or no supplementation in 262 participants. (95% CI=-3.22--1.09)Benefit seen | -2.15 pg/mL | 262 | — | Meta-analysis · 2021 | PMID 34187123 |
| CRP | No significant benefit found for CRP vs control in 50 trials. (95% CI: -9.23, 2.01)No clear benefit | no number reported | 50 trials | — | Meta-analysis · 2020 | PMID 32394508 |
| fasting glucose | Fasting glucose reduced by 15.18 vs control in 50 trials. (95% CI: -19.82, -10.55)Benefit seen | -15.18 | 50 trials | — | Meta-analysis · 2020 | PMID 32394508 |
| HbA1C levels | HbA1C levels reduced by 0.45 vs control in 50 trials. (95% CI: -0.66, -0.23)Benefit seen | -0.45 | 50 trials | — | Meta-analysis · 2020 | PMID 32394508 |
| LDL-cholesterol | LDL-cholesterol reduced by 18.45 vs control in 50 trials. (95% CI: -22.44, -14.94)Benefit seen | -18.45 | 50 trials | — | Meta-analysis · 2020 | PMID 32394508 |
| MDA levels | No significant benefit found for MDA levels vs control in 50 trials. (95% CI: -2.18, 0.27)No clear benefit | no number reported | 50 trials | — | Meta-analysis · 2020 | PMID 32394508 |
| TAC | No significant benefit found for TAC vs control in 50 trials. (95% CI: 0.00, 0.63)No clear benefit | no number reported | 50 trials | — | Meta-analysis · 2020 | PMID 32394508 |
| TNF-α | No significant benefit found for TNF-α vs control in 50 trials. (95% CI: -3.23, 0.86)No clear benefit | no number reported | 50 trials | — | Meta-analysis · 2020 | PMID 32394508 |
| total cholesterol | Total cholesterol reduced by 16.80 vs control in 50 trials. (95% CI: -21.04, -12.55)Benefit seen | -16.80 | 50 trials | — | Meta-analysis · 2020 | PMID 32394508 |
| triglycerides | Triglycerides reduced by 15.73 vs control in 50 trials. (95% CI: -20.77, -10.69)Benefit seen | -15.73 | 50 trials | — | Meta-analysis · 2020 | PMID 32394508 |
| VLDL-cholesterol | VLDL-cholesterol reduced by 3.72 vs control in 50 trials. (95% CI: -7.27, -0.18)Benefit seen | -3.72 | 50 trials | — | Meta-analysis · 2020 | PMID 32394508 |
| C-reactive protein (CRP) | CRP levels significantly reduced with an SMD of -0.35 compared to control in a meta-analysis of 12 trials. (95% CI: -0.59, -0.12, P < 0.001)Benefit seen | -0.35 SMD | — | — | Meta-analysis · 2020 | PMID 33183658 |
| Malondialdehyde (MDA) | MDA concentrations significantly reduced with an SMD of -0.56 compared to control in a meta-analysis of 12 trials. (95% CI: -0.98, -0.15, P < 0.001)Benefit seen | -0.56 SMD | — | — | Meta-analysis · 2020 | PMID 33183658 |
| Total antioxidant capacity (TAC) | TAC levels significantly increased with an SMD of 0.48 compared to control in a meta-analysis of 12 trials. (95% CI: 0.09, 0.87, P = 0.01)Benefit seen | 0.48 SMD | — | — | Meta-analysis · 2020 | PMID 33183658 |
| Tumor necrosis factor-alpha (TNF-α) | TNF-α levels showed no significant change compared to control in a meta-analysis of 12 trials. (95% CI: -0.70, 0.01, P = 0.05)No clear benefit | no number reported | — | — | Meta-analysis · 2020 | PMID 33183658 |
| CRP | CRP levels decreased by SMD -0.60 vs placebo in 1033 people. (95% CI: from -0.96 to -0.23; P = 0.00)Benefit seen | -0.60 SMD | 1033 | — | Systematic review · 2024 | PMID 37859312 |
| IL-6 | IL-6 levels decreased by SMD -0.54 vs placebo in 1033 people. (95% CI: from -1.01 to -0.07; P = 0.02)Benefit seen | -0.54 SMD | 1033 | — | Systematic review · 2024 | PMID 37859312 |
| MDA | MDA levels decreased by SMD -1.28 vs placebo in 1033 people. (95% CI: from -2.11 to -0.46; P = 0.00)Benefit seen | -1.28 SMD | 1033 | — | Systematic review · 2024 | PMID 37859312 |
| SOD | SOD levels increased by SMD 1.35 vs placebo in 1033 people. (95% CI, from 0.77 to 1.93; P = 0.00)Benefit seen | 1.35 SMD | 1033 | — | Systematic review · 2024 | PMID 37859312 |
| TAC | TAC levels increased by SMD 2.82 vs placebo in 1033 people. (95% CI, from 0.55 to 5.084; P = 0.01)Benefit seen | 2.82 SMD | 1033 | — | Systematic review · 2024 | PMID 37859312 |
| TNF-α | TNF-α levels decreased by SMD -0.53 vs placebo in 1033 people. (95% CI: from -0.74 to -0.53; P = 0.00)Benefit seen | -0.53 SMD | 1033 | — | Systematic review · 2024 | PMID 37859312 |